Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Center for Outcomes Research and Evaluation, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Eur J Neurol. 2021 Jun;28(6):1812-1819. doi: 10.1111/ene.14822. Epub 2021 Mar 26.
There is concern that the Patient Health Questionnaire-9 (PHQ-9) depression scale may be impacted by the presence of somatic symptoms (differential item functioning [DIF]) in patients with neurological conditions. We evaluated the PHQ-9 for the presence and impact of DIF in large clinical samples of neurological patients.
We conducted a cross-sectional study of patients seen at the Cleveland Clinic Cerebrovascular, Headache, Movement Disorder, and Neuromuscular clinics who completed the PHQ-9 and patient-reported disease severity measures as part of standard care between 29 July 2008 and 21 February 2013. We evaluated PHQ-9 items for DIF with respect to disease-specific severity for each condition. Salient DIF impact was characterized as a difference between DIF-adjusted and unadjusted PHQ-9 scores.
Included in the study were 2112 patients with stroke, 8221 with migraine, 440 with amyotrophic lateral sclerosis (ALS), and 5022 with Parkinson disease (PD). Several PHQ-9 items demonstrated DIF with respect to disease-specific severity, although salient DIF was present in very few patients (stroke, n = 0; migraine, n = 1; ALS, n = 13; PD, n = 1).
PHQ-9 items function consistently across disease severity, with salient levels of DIF impact found only for a very small proportion of people. These results suggest that the PHQ-9 provides a consistent measure of depression severity among people with neurological conditions associated with somatic symptoms that overlap with depression.
人们担心在患有神经系统疾病的患者中,躯体症状(差异项目功能[DIF])可能会影响患者健康问卷-9(PHQ-9)抑郁量表。我们在大量的神经系统疾病患者的临床样本中评估了 PHQ-9 存在和 DIF 的影响。
我们对 2008 年 7 月 29 日至 2013 年 2 月 21 日期间在克利夫兰诊所脑血管病、头痛、运动障碍和神经肌肉诊所就诊并完成 PHQ-9 和患者报告疾病严重程度测量的患者进行了横断面研究,这些患者的评估是作为标准护理的一部分。我们针对每种疾病的特定严重程度评估了 PHQ-9 项目的 DIF。显著 DIF 影响的特征是 DIF 调整和未调整 PHQ-9 评分之间的差异。
研究包括 2112 例脑卒中患者、8221 例偏头痛患者、440 例肌萎缩侧索硬化症(ALS)患者和 5022 例帕金森病(PD)患者。尽管在极少数患者中存在明显的 DIF(脑卒中患者 n=0;偏头痛患者 n=1;ALS 患者 n=13;PD 患者 n=1),但几个 PHQ-9 项目显示出与疾病特异性严重程度有关的 DIF。
PHQ-9 项目在疾病严重程度上具有一致的功能,仅在极少数人身上发现具有明显 DIF 影响的水平。这些结果表明,PHQ-9 为与抑郁重叠的躯体症状相关的神经系统疾病患者提供了一致的抑郁严重程度衡量标准。